通过刺激抗瘤免疫力,ACSL4倒退抑制了结直肠癌的进展
Yiming Liu1, Xingyu Jiang1, Dongquan Jing1
1Institute of Translational Medicine, China Pharmaceutical University, Nanjing, Jiangsu 211198, PR China; Translational Medicine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, PR China.
长链乙基-CoA合成酶4 (ACSL4) 抑制了结直肠癌 (CRC) 的抗瘤免疫力. 向ACSL4可以通过促进T细胞透和对PD-L1阻塞的反应来提高免疫疗法的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 长链乙基-CoA合成酶4 (ACSL4) 与瘤进展有关.
- 它在结直肠癌 (CRC) 免疫微环境中的作用尚不清楚.
研究的目的:
- 研究ACSL4对CRC进展和抗瘤免疫力的影响.
- 确定ACSL4作为CRC免疫疗法的治疗点的潜力.
主要方法:
- 在CRC组织中分析了ACSL4表达和患者预后.
- 在CRC细胞系和动物模型中评估了ACSL4的影响.
- 评估了免疫细胞透,信号通路和PD-L1阻断的有效性.
主要成果:
- 升高的ACSL4水平与CRC患者的预后不佳相关.
- 抑制ACSL4抑制了瘤生长,并增强了CD8+ T细胞的透.
- 缺乏ACSL4可提高免疫相关基因的调节,并改善对PD-L1阻塞的反应.
结论:
- 通过RIG-I-MAVS-IFN通路,ACSL4抑制了CRC中的抗瘤免疫力.
- ACSL4代表了增强CRC免疫疗法的有前途的治疗标.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Inhibition of Cdk Activity
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
